Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PPIB | P23284 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | PPIG | Q13427 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16837304 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL5845815 | 0.84 | CXCR1 (0.53) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL23182899 | 0.81 | ALDH1A1 (0.54) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL1404080 | 0.81 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL13637085 | 0.81 | ALDH1A1 (0.54) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL28492074 | 0.81 | CXCR1 (0.67) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL12477150 | 0.80 | CXCR1 (0.62) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL113044 | 0.77 | MAPT (0.52) | KDM4EALDH1A1GAAMAPTCYP3A4 | |
| SCHEMBL654389 | 0.77 | GAA (0.66) | KDM4EALDH1A1SMN1; SMN2GAANPSR1 | |
| SCHEMBL6255747 | 0.77 | MAPT (0.50) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578725-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004056777-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
| US-5753670-A | ANTICOAGULANTS | THE GREEN CROSS CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5635527-A | ANTAGONIST OF PLATELET MEMBRANE GLYCOPROTEIN; TREATMENT OF THROMBOTIC DISEASES | THE GREEN CROSS CORPORATION (JP) | 1997-06-03 | — | — | US | disclosed |
| EP-0712844-A1 | NOVEL FUSED-RING CARBOXYLIC ACID COMPOUND OR SALT THEREOF, AND MEDICINAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | MTTP, CETP, APOB | KDM4E 3437/4885ALDH1A1 1592/4885SMN1; SMN2 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.